Israeli drug maker Teva has beaten out rivals Pfizer and Actavis to acquire German generic drug maker Ratiopharm GmbH — in a deal announced Thursday worth some euro3.6 billion, or nearly $5 billion. Teva Pharmaceutical Industries Ltd.'s successful bid will give it a lofty perch in the lucrative German generic market and is the second big acquisition in two ...

FRANKFURT (Reuters) - Israel's Teva <TEVA.TA> has won the battle for German generic drugmaker Ratiopharm, paying an enterprise value of 3.625 billion euros to fix the industry leader's weakness in the world's second-largest generics market. Teva, which beat U.S. drugs powerhouse Pfizer <PFE.N> and Iceland's Actavis in the race ...

FRANKFURT/COLOGNE (Reuters) - The tussle over German generic drugs maker Ratiopharm is drawing to a close as the three remaining contenders square off in the final round of bidding, sources close to the deal told Reuters on Wednesday. Pfizer <PFE.N> will submit its bid on Wednesday, a person briefed on the matter said. Rival bidder Actavis of ...

NEW YORK (Reuters) - Pfizer Inc <PFE.N> is set to present a nearly $4 billion offer for German generic-drug maker Ratiopharm GmbH this week, competing against rival bids from Teva Pharmaceutical Industries Ltd <TEVA.TA> and Actavis, sources familiar with the situation said on Tuesday. Pfizer had previously cooled on Ratiopharm, but was asked to rejoin ...